Difference between revisions of "Tendering process for pneumococcal conjugate vaccine"
From Testiwiki
m |
m |
||
| Line 9: | Line 9: | ||
== Scope == | == Scope == | ||
* We restrict the analysis to vaccination within the infant immunisation programme. | * We restrict the analysis to vaccination within the infant immunisation programme. | ||
| − | * We specify the tendering criteria | + | * We specify the tendering criteria ([[Vertailuperusteet|vertailuperusteet]]) for choosing the pneumococcal conjugate vaccine. |
* Tavoitteena on määritellä tarjouskilpailun kokonaistaloudellinen valintaperuste. | * Tavoitteena on määritellä tarjouskilpailun kokonaistaloudellinen valintaperuste. | ||
| − | * We discuss | + | * We discuss assumptions underlying the epidemiological model and the cost-effectiveness analysis. |
* The analysis is based on current knowledge of the efficacy and impact of pneumococcal conjugate vaccines. | * The analysis is based on current knowledge of the efficacy and impact of pneumococcal conjugate vaccines. | ||
| − | * The procurement can only involve products that have trading | + | * The procurement can only involve products that have trading license in Finland (see [http://www.finlex.fi/fi/laki/ajantasa/1987/19870395/#L4P20a Lääkelain 20a§]). |
* Valmisteltava hankinta on [http://www.finlex.fi/fi/laki/ajantasa/2007/20070348 julkisista hankinnoista annetun lain] mukainen. | * Valmisteltava hankinta on [http://www.finlex.fi/fi/laki/ajantasa/2007/20070348 julkisista hankinnoista annetun lain] mukainen. | ||
* The discussion on these pages does not bind the preparation of the procurement. | * The discussion on these pages does not bind the preparation of the procurement. | ||
Revision as of 12:41, 18 June 2014
This page is a assessment.
The page identifier is Op_en6352 |
|---|
| Moderator:Nobody (see all) Click here to sign up. |
|
Give your opinion to the peer rating of the content of this page. |
| Upload data
|
Contents
Question
- How should vaccine products be compared in the national procurement of the pneumococcal conjugate vaccine.
Scope
- We restrict the analysis to vaccination within the infant immunisation programme.
- We specify the tendering criteria (vertailuperusteet) for choosing the pneumococcal conjugate vaccine.
- Tavoitteena on määritellä tarjouskilpailun kokonaistaloudellinen valintaperuste.
- We discuss assumptions underlying the epidemiological model and the cost-effectiveness analysis.
- The analysis is based on current knowledge of the efficacy and impact of pneumococcal conjugate vaccines.
- The procurement can only involve products that have trading license in Finland (see Lääkelain 20a§).
- Valmisteltava hankinta on julkisista hankinnoista annetun lain mukainen.
- The discussion on these pages does not bind the preparation of the procurement.
Answer
Rationale
The rationaly has been summarised in the following 3 pages (currently in Finnish): Vertailuperusteet, Epidemiologinen_mallinnus ja Taloudellinen arviointi.
Rokotteiden vertailu perustuu hintaan ja hyötyyn (ks. vertailuperusteet). Epidemiolognen hyöty tarkoittaa arvioitua vakavien pneumokokkitapausten vähenemää, jos rokote otettaisiin kansalliseen rokotusohjelmaan. Arvio tehdään epidemiologisen mallin avulla. Rokotusohjelman vaikuttavuus määrätään epidemiologisen mallin antaman arvion perusteella terveyteen liittyvänä elämänlaadun muutoksena. Kustannusvaikuttavin rokotevalmiste valitaan taloudellisen arvioinnin menetelmin.
